AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10326324 — intervention group
Group type: COMPARATOR
Intervention: Low dose cyclosporin A
Number of subjects: 208
Study 8567042 — intervention group
Group type: COMPARATOR
Intervention: Sodium-restricted diet (50 mmol/24 h)
Number of subjects: 32
Study 8567042 — intervention group
Group type: COMPARATOR
Intervention: Sodium-replete diet (200 mmol/24 h)
Number of subjects: 32
Study 8567042 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren (600 mg, single oral dose) during high sodium period
Number of subjects: 32
Study 8392419 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave electron paramagnetic resonance (CW‐EPR) dosimetry using alanine
Number of subjects: 0
Study 8392419 — intervention group
Group type: COMPARATOR
Intervention: Thermoluminescent dosimetry (TLD)
Number of subjects: 0
Study 3554643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (15‐17 mg/kg/day)
Number of subjects: 117
Study 3554643 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (15‐17 mg/kg/day) + Prednisolone (0.3 mg/kg/day)
Number of subjects: 117
Study 30863532 — intervention group
Group type: EXPERIMENTAL
Intervention: Newsletter plus handwritten Post-it®
Number of subjects: 826
Study 30863532 — intervention group
Group type: EXPERIMENTAL
Intervention: Newsletter plus printed Post-it®
Number of subjects: 826
Study 30863532 — intervention group
Group type: EXPERIMENTAL
Intervention: Newsletter only
Number of subjects: 826
Study 30863532 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwritten Post-it® only
Number of subjects: 826
Study 30863532 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed Post-it® only
Number of subjects: 826
Study 30863532 — intervention group
Group type: EXPERIMENTAL
Intervention: No Post-it®
Number of subjects: 826
Study 30863532 — intervention group
Group type: COMPARATOR
Intervention: No newsletter or Post-it®
Number of subjects: 826
Study 27177100 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart‐Gallbladder acupuncture treatment
Number of subjects: 60
Study 27177100 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture treatment
Number of subjects: 60
Study 25707624 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-438 40 mg once daily for 7 days
Number of subjects: 108
Study 25707624 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-438 (all dose levels)
Number of subjects: 108
Study 22925832 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 kilocalories per kilogram of body weight per week (KKW) for 12 weeks
Number of subjects: 0
Study 22925832 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 KKW for 12 weeks
Number of subjects: 0
Study 22925832 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (both doses)
Number of subjects: 0
Study 22925832 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise treatment
Number of subjects: 0
Study 22925832 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant medications
Number of subjects: 0
Study 22159777 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 57
Study 22159777 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C/E supplementation (AS)
Number of subjects: 57
Study 22159777 — intervention group
Group type: EXPERIMENTAL
Intervention: AS + RT
Number of subjects: 57
Study 22159777 — intervention group
Group type: COMPARATOR
Intervention: Control - placebo
Number of subjects: 57
Study 19346877 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise and nutrition program
Number of subjects: 13
Study 19346877 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 13
Study 16979011 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 458
Study 15568149 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time myocardial contrast echocardiography (MCE)
Number of subjects: 66
Study 15568149 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-sestamibi single photon emission computed tomography (SPECT)
Number of subjects: 66
Study 11401657 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 58
Study 11401657 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 58
Study 9474071 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency department visits (3 or more in the prior 6 months)
Number of subjects: 284
Study 9474071 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty performing work or activities due to physical health in the 4 weeks prior
Number of subjects: 284
Study 9474071 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuing hospital-based treatment within 24 hours without achieving a peak expiratory flow rate of at least 50% of predicted
Number of subjects: 284
Study 7527327 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 7527327 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 7527327 — intervention group
Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 0
Study 2544254 — intervention group
Group type: EXPERIMENTAL
Intervention: Central parenteral nutrition (CPN)
Number of subjects: 31
Study 2544254 — intervention group
Group type: COMPARATOR
Intervention: Peripheral parenteral nutrition (PPN) plus enteral nutrition (EN)
Number of subjects: 31
Study 2544254 — intervention group
Group type: COMPARATOR
Intervention: Enteral nutrition (EN)
Number of subjects: 31
Study 31659803 — intervention group
Group type: EXPERIMENTAL
Intervention: GB001 (30 mg) once daily for 28 days
Number of subjects: 36
Study 31659803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29868915 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of pure (‐)‐epicatechin
Number of subjects: 48
Study 29868915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 26569451 — intervention group
Group type: EXPERIMENTAL
Intervention: Light intensity treadmill walking exercise
Number of subjects: 24
Study 26569451 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity treadmill walking exercise
Number of subjects: 24
Study 26569451 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity treadmill walking exercise
Number of subjects: 24
Study 26569451 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest
Number of subjects: 24
Study 24056269 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic treadmill training (ATM)
Number of subjects: 60
Study 24056269 — intervention group
Group type: COMPARATOR
Intervention: Land-based treadmill training (LTM)
Number of subjects: 60
Study 21944980 — intervention group
Group type: EXPERIMENTAL
Intervention: End-range mobilization/scapular mobilization treatment approach (EMSMTA)
Number of subjects: 34
Study 21944980 — intervention group
Group type: COMPARATOR
Intervention: Standardized physical therapy program (criteria-control group)
Number of subjects: 34
Study 20739447 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins (B complex, C, and E)
Number of subjects: 674
Study 20739447 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A + β‐carotene
Number of subjects: 674
Study 20739447 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins (B complex, C, and E) among women with CD4+ T-cell counts ≥ 350 cells/μL
Number of subjects: 674
Study 20739447 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 674
Study 18288087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 0
Study 18288087 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0
Study 15820454 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral linezolid
Number of subjects: 60
Study 15820454 — intervention group
Group type: COMPARATOR
Intervention: Intravenous vancomycin
Number of subjects: 60
Study 12595859 — intervention group
Group type: EXPERIMENTAL
Intervention: Premounted stents
Number of subjects: 123
Study 12595859 — intervention group
Group type: COMPARATOR
Intervention: Unmounted stents
Number of subjects: 123
Study 10594478 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (200 mg) plus Acetylsalicylic Acid (25 mg)
Number of subjects: 0
Study 10594478 — intervention group
Group type: COMPARATOR
Intervention: Placebo or Acetylsalicylic Acid (ASA) alone
Number of subjects: 0
Study 1978472 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (mean daily dose 437 mg)
Number of subjects: 96
Study 1978472 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (mean daily dose 10.6 mg)
Number of subjects: 96
Study 1978472 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (control)
Number of subjects: 96
Study 104084 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluorothymidine (5 drops daily)
Number of subjects: 56
Study 104084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 56
Study 31915048 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week of antibiotic therapy for residual osteomyelitis
Number of subjects: 400
Study 31915048 — intervention group
Group type: COMPARATOR
Intervention: 3 weeks of antibiotic therapy for residual osteomyelitis
Number of subjects: 400
Study 31915048 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 day of antibiotic therapy for remaining soft tissue infection
Number of subjects: 400
Study 31915048 — intervention group
Group type: COMPARATOR
Intervention: 4 days of antibiotic therapy for remaining soft tissue infection
Number of subjects: 400
Study 31915048 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 days of antibiotic therapy for soft tissue infections
Number of subjects: 400
Study 31915048 — intervention group
Group type: COMPARATOR
Intervention: 20 days of antibiotic therapy for soft tissue infections
Number of subjects: 400
Study 31915048 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks of antibiotic therapy for osteomyelitis
Number of subjects: 400
Study 31915048 — intervention group
Group type: COMPARATOR
Intervention: 6 weeks of antibiotic therapy for osteomyelitis
Number of subjects: 400
Study 30707056 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCO-NHB v2
Number of subjects: 102
Study 30707056 — intervention group
Group type: EXPERIMENTAL
Intervention: Thresholds for ASCO-NHB v2
Number of subjects: 102
Study 30707056 — intervention group
Group type: EXPERIMENTAL
Intervention: ESMO-MCBS v1.1
Number of subjects: 102
Study 30707056 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordant studies
Number of subjects: 102
Study 27693478 — intervention group
Group type: EXPERIMENTAL
Intervention: Dismembered pyeloplasty without external nephro-ureteric stent (group A)
Number of subjects: 30
Study 27693478 — intervention group
Group type: COMPARATOR
Intervention: Dismembered pyeloplasty with external nephro-ureteric stent (ENUS) (group B)
Number of subjects: 30
Study 26048004 — intervention group
Group type: EXPERIMENTAL
Intervention: Aware condition (participants informed of UEM presence)
Number of subjects: 39
Study 26048004 — intervention group
Group type: COMPARATOR
Intervention: Unaware condition (participants not informed of UEM presence)
Number of subjects: 39
Study 23379539 — intervention group
Group type: EXPERIMENTAL
Intervention: HA/β‐TCP
Number of subjects: 30
Study 23379539 — intervention group
Group type: EXPERIMENTAL
Intervention: HA/β‐TCP-EMD
Number of subjects: 30
Study 22204724 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab initiation (chemotherapy with bevacizumab added in cycles 2 through 6 and placebo in cycles 7 through 22)
Number of subjects: 1873
Study 22204724 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab throughout (chemotherapy with bevacizumab added in cycles 2 through 22)
Number of subjects: 1873
Study 22204724 — intervention group
Group type: COMPARATOR
Intervention: Control (chemotherapy with placebo added in cycles 2 through 22)
Number of subjects: 1873
Study 22204724 — intervention group
Group type: COMPARATOR
Intervention: Control (chemotherapy with placebo)
Number of subjects: 1873
Study 22204724 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab initiation
Number of subjects: 1873
Study 22204724 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab throughout
Number of subjects: 1873
Study 22204724 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1873
Study 19367154 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV suppressive therapy for 4-6 years
Number of subjects: 0
Study 19367154 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV suppressive therapy
Number of subjects: 0
Study 17323789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg single dose
Number of subjects: 25
Study 17323789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 2.5 mg single dose
Number of subjects: 25
Study 17323789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 5 mg single dose
Number of subjects: 25
Study 17323789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 5 mg/day for 7 days
Number of subjects: 25
Study 17323789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod multiple-dose administration
Number of subjects: 25
Study 17323789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod single and multiple doses
Number of subjects: 25
Study 17323789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 5 mg/day multiple dose
Number of subjects: 25
Study 17323789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod first dose
Number of subjects: 25
Study 15247960 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 44
Study 15247960 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 44
Study 12434778 — intervention group
Group type: EXPERIMENTAL
Intervention: OSHA Local Emphasis Program (LEP) for ergonomics; inspections initiated between 1992 and 1995.
Number of subjects: 14
Study 12434778 — intervention group
Group type: COMPARATOR
Intervention: New Hampshire employers not receiving an inspection focused on upper extremity cumulative trauma hazards.
Number of subjects: 14
Study 9845149 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal position of the distal spring lead in the right ventricle
Number of subjects: 20
Study 9845149 — intervention group
Group type: COMPARATOR
Intervention: Non-septal position of the distal spring lead in the right ventricle
Number of subjects: 20
Study 7517171 — intervention group
Group type: EXPERIMENTAL
Intervention: FK-506
Number of subjects: 48
Study 7517171 — intervention group
Group type: EXPERIMENTAL
Intervention: FK-506 (no prednisone)
Number of subjects: 48
Study 7517171 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 48
Study 3198303 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 10
Study 3198303 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol plus nifedipine (10 mg t.i.d.)
Number of subjects: 10
Study 3198303 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (10 mg t.i.d.)
Number of subjects: 10
Study 3198303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 477047 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg 3H‐digoxin intravenously and 0.125 mg orally as an alcoholic solution
Number of subjects: 12
Study 477047 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg unlabelled digoxin intravenously or a digoxin tablet
Number of subjects: 12
Study 477047 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups of patients
Number of subjects: 12
Study 30717153 — intervention group
Group type: EXPERIMENTAL
Intervention: DW2009 (800 mg/day)
Number of subjects: 100
Study 30717153 — intervention group
Group type: COMPARATOR
Intervention: Placebo (800 mg/day)
Number of subjects: 100
Study 28195387 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 5213
Study 28195387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5213
Study 25961136 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily TPTD for 24 months
Number of subjects: 150
Study 25961136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical TPTD (four 3-month cycles)
Number of subjects: 150
Study 25961136 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily TPTD for 24 months in ALN-Rx women
Number of subjects: 150
Study 25961136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical TPTD (four 3-month cycles) in ALN-Rx women
Number of subjects: 150
Study 23566363 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and Brief Intervention (SBI)
Number of subjects: 700
Study 23566363 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo control
Number of subjects: 700
Study 22613418 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed red blood cells (PRBCs) transfusion during liver transplantation (group LP)
Number of subjects: 52
Study 22613418 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed red blood cells (PRBCs) transfusion during spinal surgery (group SP)
Number of subjects: 52
Study 22613418 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline infusion during spinal surgery (group SN)
Number of subjects: 52
Study 19906909 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 microg of the H5N1 vaccine (one or two doses)
Number of subjects: 480
Study 19906909 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 microg of the H5N1 vaccine (single dose)
Number of subjects: 480
Study 19906909 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 microg of the H5N1 vaccine (single dose)
Number of subjects: 480
Study 19906909 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 microg of the H5N1 vaccine (one injection)
Number of subjects: 480
Study 19906909 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 microg of the H5N1 vaccine
Number of subjects: 480
Study 17914516 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mitomycin C (MMC) 0.4 mg/mL for 4 minutes
Number of subjects: 20
Study 17914516 — intervention group
Group type: COMPARATOR
Intervention: No mitomycin C (non-MMC)
Number of subjects: 20
Study 16275598 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 47
Study 16275598 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 47
Study 16275598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 47
Study 16275598 — intervention group
Group type: COMPARATOR
Intervention: All three drugs (Desipramine, Amitriptyline, Fluoxetine)
Number of subjects: 47
Study 11861354 — intervention group
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide (iNO) 10 ppm in 100% oxygen
Number of subjects: 14
Study 10453869 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidity
Number of subjects: 38
Study 10453869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold passover humidity
Number of subjects: 38
Study 10453869 — intervention group
Group type: COMPARATOR
Intervention: No humidity (washout period)
Number of subjects: 38
Study 7888515 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane-based anaesthesia
Number of subjects: 150
Study 7888515 — intervention group
Group type: COMPARATOR
Intervention: Propofol-based anaesthesia
Number of subjects: 150
Study 7888515 — intervention group
Group type: EXPERIMENTAL
Intervention: First 8 days of the menstrual cycle (in isoflurane group)
Number of subjects: 150
Study 2266675 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 82
Study 2266675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 535856 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (specific types not mentioned)
Number of subjects: 0
Study 535856 — intervention group
Group type: COMPARATOR
Intervention: Two oral contraceptives (different in dosage)
Number of subjects: 0
Study 31939768 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher trait-level intergroup anxiety
Number of subjects: 0
Study 31939768 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait-level intergroup anxiety and state-level comfort
Number of subjects: 0
Study 30920716 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpedal approach
Number of subjects: 0
Study 30920716 — intervention group
Group type: COMPARATOR
Intervention: Femoral approach
Number of subjects: 0
Study 28575534 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CCL2 levels
Number of subjects: 437
Study 28575534 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher IL-10 levels
Number of subjects: 437
Study 28575534 — intervention group
Group type: COMPARATOR
Intervention: Higher IL-6 levels
Number of subjects: 437
Study 25366519 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month training intervention (N=16)
Number of subjects: 37
Study 25366519 — intervention group
Group type: COMPARATOR
Intervention: Usual care (N=11)
Number of subjects: 37
Study 25366519 — intervention group
Group type: EXPERIMENTAL
Intervention: pwMS (N=37)
Number of subjects: 37
Study 23988507 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-rate (HDR) brachytherapy (BT) boost after external beam irradiation (mean dose 62 Gy, range 50-70 Gy)
Number of subjects: 60
Study 23988507 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy (RCT) with cisplatin
Number of subjects: 60
Study 23988507 — intervention group
Group type: COMPARATOR
Intervention: Tumor size (T1-T2-T3) vs. T4
Number of subjects: 60
Study 23988507 — intervention group
Group type: COMPARATOR
Intervention: Nodal status (N0 vs. N+)
Number of subjects: 60
Study 23988507 — intervention group
Group type: COMPARATOR
Intervention: Histologic grade (1-2)
Number of subjects: 60
Study 23988507 — intervention group
Group type: COMPARATOR
Intervention: Radiochemotherapy (RCT)
Number of subjects: 60
Study 21819160 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin/metformin XR 5 mg/500 mg FDC
Number of subjects: 30
Study 21819160 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin/metformin XR 5 mg/1000 mg FDC
Number of subjects: 30
Study 21819160 — intervention group
Group type: COMPARATOR
Intervention: saxagliptin 5 mg and metformin XR 500 mg co-administered
Number of subjects: 30
Study 19376321 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 2130
Study 19376321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2130
Study 16340517 — intervention group
Group type: EXPERIMENTAL
Intervention: Free nicotine replacement therapy (NRT) voucher
Number of subjects: 732
Study 16340517 — intervention group
Group type: EXPERIMENTAL
Intervention: Better Quit® (BQ) cigarette substitute
Number of subjects: 732